1113-62-8

Upstream product

• 10557-82-1 3,4,5-trimethylisoxazole 
• 3002-24-2 hexane-2,4-dione 
• 815-57-6 3-Methyl-2,4-pentanedione 
• 60-29-7 diethyl ether 
• 1522-25-4 4-hydroxy-3-methylpent-3-en-2-one 
• 123-54-6 acetylacetone 
• 15435-71-9 sodium acetoacetonate 

Downstream Products

• 7664-41-7 ammonia 
• 64-19-7 acetic acid 
• 78-93-3 butanone 
• 91591-64-9 2-chloro-4,5,6-trimethylpyridine-3-carbonitrile 
• 81818-60-2 1-Phenyl-4,5,6-trimethylpyrimidin-2(1H)-one 
• 17697-92-6 4,5,6-trimethyl-2,5-dihydro-2-thioxopyrimidine 
• 614-23-3 N-benzoylthiourea 
• 85741-87-3 N-benzoyl-N'-(1,2-dimethyl-3-oxo-1-butenyl)thiourea 
• 26823-24-5 1-Phenyl-3-(1,2-dimethyl-3-oxo-1-butenyl)urea 

Relevant academic research and scientific papers

Molecular structure and intramolecular hydrogen bond strength of 3-methyl-4-amino-3-penten-2-one and its N–Me and N-Ph substitutions by experimental and theoretical methods

In the present work, molecular structures and intramolecular hydrogen bonding (IHB) of 3-methyl-4-amino-3-penten-2-one, 3-MeAPO, 3-methyl-4-methylamino-3-penten-2-one, 3-Me-MeAPO, and the 3-methyl-4-phenylamino-3-penten-2-one, 3-Me-PhAPO have been investi

5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES

The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Photocycloaddition of aromatic and aliphatic aldehydes to isoxazoles: Cycloaddition reactivity and stability studies

The first photocycloadditions of aromatic and aliphatic aldehydes to methylated isoxazoles are reported. The reactions lead solely to the exo-adducts with high regio- and diastereoselectivities. Ring methylation of the isoxazole substrates is crucial for high conversions and product stability. The 6-arylated bicyclic oxetanes 9a-9c were characterized by X-ray structure analyses and showed the highest thermal stabilities. All oxetanes formed from isoxazoles were highly acid-sensitive and also thermally unstable. Cleavage to the original substrates is dominant and the isoxazole derived oxetanes show type T photochromism.

KINETICS OF CYCLIZATION OF 1-PHENYL-3-(1,2-DIMETHYL-3-OXO-1-BUTENYL)UREA AND ETHYL 2-METHYL-3-N-(N'-PHENYLUREIDO)-2-BUTENOATE

1-Phenyl-3-(1,2-dimethyl-3-oxo-1-butenyl)urea (III) has been prepared by reaction of phenyl isocyanate with 4-amino-3-methyl-3-penten-2-one (I).Ethyl 2-methyl-3-N-(N'-phenylureido)-2-butenoate (V) has been prepared by analogous reaction with ethyl 3-amino